Drugs / Anacetrapib
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01122667 | Jun 2010 → Jun 2011 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01114490 | May → Jul 2010 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00990808 | Nov 2009 → Jun 2011 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00565006 | Jul → Sep 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00565292 | Jul → Aug 2006 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00977288 | Sep 2009 → Mar 2010 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00325455 | Jun 2006 → Feb 2007 | hyperlipidemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 38 trials · 6 met primary | ||||||
| Phase 3 | NCT01841684 | Jun 2013 → Jun 2014 | homozygous familial hypercholesterolemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01860729 | May 2013 → May 2015 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01824238 | May 2013 → May 2014 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01760460 | Mar 2013 → Mar 2015 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01717300 | Nov 2012 → Oct 2014 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01524289 | Feb 2012 → Feb 2014 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01252953 | Jun 2011 → Jan 2017 overdue | atherosclerotic cardiovascular disease | University of Oxford | Active not recruiting | Met primary |
| Phase 3 | NCT00685776 | Mar 2008 → Jul 2009 | coronary artery disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2017-08-29 | Merck Sharp & Dohme LLC | Results Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease merck.com ↗
The safety of anacetrapib was generally consistent with data from earlier trials of the drug. |
| 2017-06-27 | Merck Sharp & Dohme LLC | Results Merck Provides Update on REVEAL Outcomes Study of Anacetrapib merck.com ↗
The safety profile of anacetrapib in the early analysis was generally consistent with that demonstrated in previous studies of the drug, including accumulation of anacetrapib in adipose tissue, as has been previously reported. |
| 2012-08-26 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Cardiovascular Development Programs merck.com ↗
Merck also today provided information about a different method to more accurately measure LDL-C when patients are treated with anacetrapib, an investigational CETP-inhibitor. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-11 | Merck Sharp & Dohme LLC | Merck Provides Update on Anacetrapib Development Program merck.com ↗ |
| 2017-08-29 | Merck Sharp & Dohme LLC | Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease merck.com ↗ |
| 2017-06-27 | Merck Sharp & Dohme LLC | Merck Provides Update on REVEAL Outcomes Study of Anacetrapib merck.com ↗ |
| 2012-08-26 | Merck Sharp & Dohme LLC | Merck Provides Update on Cardiovascular Development Programs merck.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anacetrapib | “Anacetrapib (MK-0859) is a CETP inhibitor currently under development.” PMID 18068514 ↗ Dec 2007 |
| Known as | ANA | “We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein...” PMID 22180633 ↗ Dec 20111“This study evaluated the effects of anacetrapib (ANA) on lipids and safety when administered as monotherapy or in combination with atorvastatin (ATV) in Japanese patients...” PMID 23958252 ↗ Jun 2013 |
| Known as | MK0859 | “Anacetrapib (MK-0859) is a CETP inhibitor currently under development.” PMID 18068514 ↗ Dec 20074“single dose administration of anacetrapib (MK0859) 100 mg oral tablet” NCT01122667 ↗ “single dose administration of anacetrapib (MK0859) 100 mg oral tablet” NCT01114490 ↗ “transfer protein inhibitor anacetrapib (MK-0859) in patients” PMID 21982664 ↗ Sep 2011 |
| Action | Inhibit | “Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor” PMID 24737712 ↗ Apr 2014 |
| Modality | Small molecule | — CHEMBL1800807 ↗ |
| Route | Oral | “received anacetrapib doses of 0, 10, 40, 150, or 300 mg orally once a day with a meal for 28 days.” PMID 18068514 ↗ Dec 2007 |
| Target | CETP | “anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor” PMID 28729361 ↗ Jul 2017 |